Fresenius Medical Care : comments on successful defeat of the ballot initiative Proposition 8 in California

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous Fresenius Medical Care comments on successful defeat of the ballot initiative Proposition 8 in California 07.11.2018 / 09:12 The issuer is solely responsible for the content of this announcement. Fresenius Medical Care, the world's largest provider of dialysis products and services, today released the following statement in response to the defeat of the ballot initiative Proposition 8 in California. "We are pleased that California voters have rejected Proposition 8 in yesterday's ballot election. This is a big win for California dialysis patients," said Rice Powell, CEO of Fresenius Medical Care. "Proposition 8 was a deeply flawed measure that would have dangerously reduced access for dialysis patients in California by setting arbitrary limits on what insurance companies are required to pay for dialysis care. We at Fresenius Medical Care are committed to offering high-quality products and services to our patients and will continue to do so in California and around the world." Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,872 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 329,085 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the company's website at www.freseniusmedicalcare.com. Disclaimer This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. Contact: Dr. Dominik Heger SVP & Head of Investor Relations & Corporate Communications [e-mail] P. [phone] 07.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:	English
Company:	Fresenius Medical Care AG & Co. KGaA
	Else-Kröner-Straße 1
	61352 Bad Homburg
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.freseniusmedicalcare.com
ISIN:	DE0005785802
WKN:	578580
Indices:	DAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange

End of News	DGAP News Service

742383  07.11.2018